MENU

Senior appointment demonstrates growth ambitions at Arcinova

An experienced senior business leader, Dr Gareth Jenkins CChem FRSC has joined the Alnwick, UK based firm to support it in applying new technologies which enable the implementation of continuous manufacturing processes.

Arcinova provides both integrated end to end solutions and standalone services to pharmaceutical and biotech companies across the globe. It’s offerings include drug substance synthesis, drug product manufacture, Chemistry, Manufacturing and Controls (CMC), bioanalytical and metabolism services, radiolabelling synthesis and synthesis of toxic/highly potent APIs. 

The company also provides consultancy services and works in partnership with companies throughout the drug development process.

Gareth has joined Arcinova from Britest, a manufacturing process consultancy, where he was CEO. His experience includes research, development, scale-up and commercialisation spanning laboratory, kilo-lab, pilot and commercial plant scales. 

In his new role, Gareth will focus on identifying technology that will enable Arcinova to further enhance its innovation-led approach to pharmaceutical development. An initial area of focus will be to drive Arcinova’s adoption of flexible, modular continuous manufacturing processes. In doing so, the organisation and its customers will continue to benefit from streamlined efficiencies in keeping with Arcinova’s agile approach to drug development. Another key element of Gareth’s role will be to harness the power of biology – and in particular the growing field of synthetic biology – to access complex, novel materials from simple, sustainable resources. . 

Prior to joining Arcinova, he was COO, Director and Company Secretary at AM Technology; Process Research & Development Director and Site Quality Manager at AMRI UK; and Vice President Research & Development at Excelsyn Molecular Development. Gareth also holds a PhD and BSc in Chemistry from Imperial College, London and an MBA in Entrepreneurship from Manchester Business School

Commenting on his new appointment, Gareth Jenkins said: “I’m looking forward to supporting the continued expansion of Arcinova. The company has seen impressive growth over the last two years and I feel that I am coming on board at an exciting phase in its development. 

“Arcinova’s commitment to innovation closely aligns with my passion for industrial biotechnology, synthetic biology and continuous manufacturing and process engineering.”

Ian Shott, Executive Chairman and Managing Director of Arcinova, commented: “I first worked with Gareth in 2005 when I was CEO of Excelsyn, a pharmaceutical development and manufacturing services company. I am therefore delighted to be able to welcome Gareth to the Arcinova team – and to be working with him again. 

“Gareth has a wealth of experience in biology and technology and has great ability in identifying areas of a business that can be made more efficient and sourcing the right technology to enable this. I look forward to seeing the impact he will make on Arcinova as we continue our journey and build on our success to date.”

Arcinova recently announced the award of a £1.5 million Innovate UK grant for the development of new flexible modular manufacturing technologies, a project which is set to demonstrate the operating feasibility of world first innovative continuous production tools.

The project, which will span a three-year period, will be undertaken in collaboration with a team at the University of Nottingham. 

Launched in 2016, Arcinova operates from a 15,000m2 facility on a 34-acre site, which has benefited from decades of investment as a key research and development centre for Sanofi and Covance, allowing it to offer a unique range of complementary on-site capabilities as a CRDO.

Arcinova’s senior scientific team are renowned for their world class, specialist research and development expertise and their big pharma and CRDO experience gives them extensive, broad ranging industry knowledge and insight.

Arcinova works with big pharma, specialty pharma and biotech companies across the globe, from established multinationals to emerging start-ups.